147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer. (December 2022)

Record Type:
Journal Article
Title:
147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer. (December 2022)
Main Title:
147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer
Authors:
Champiat, S.
Boyer, M.
Paz-Ares, L.
Schoenfeld, A.
Izumi, H.
Govindan, R.
Carlisle, J.
Borghaei, H.
Johnson, M.L.
Steeghs, N.
Vokes, E.E.
Dowlati, A.
Zhang, Y.
Pati, A.
Ju, C-H.
Mukherjee, S.
Chen, X.
Hashemi Sadraei, N.
Hummel, H-D.
Abstract:
Is Part Of:
Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Issue Display:
Volume 16, Issue 1 (2022)
Year:
2022
Volume:
16
Issue:
1
Issue Sort Value:
2022-0016-0001-0000
Page Start:
Page End:
Publication Date:
2022-12
Subjects:
Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:
https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:
10.1016/j.iotech.2022.100259 ↗
Languages:
English
ISSNs:
2590-0188
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
24685.xml